STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Clinical trials for STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to shrink tumors and cut radiation for young cancer patients
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (gemcitabine and cisplatin) before radiation therapy is safe and effective for children and young adults (up to age 21) with newly diagnosed nasopharyngeal carcinoma. The goal is to see if t…
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
New vaccine combo aims to train immune system against advanced head and neck cancer
Disease control Recruiting nowThis early-phase trial tests a vaccine made from a patient's own tumor cells, alone or with the immunotherapy drug pembrolizumab, for head and neck cancer that has come back or spread. The goal is to find the safest dose and see if the vaccine helps the immune system fight the ca…
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
New hope for Hard-to-Treat nasopharyngeal cancer: drug combo trial launches
Disease control Recruiting nowThis study tests whether adding the targeted drug cabozantinib to standard immunotherapy (nivolumab and ipilimumab) can help shrink or stabilize advanced nasopharyngeal cancer that has returned or spread. About 50 adults whose cancer worsened after platinum chemotherapy and immun…
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
New combo aims to keep nasopharyngeal cancer at bay longer
Disease control Recruiting nowThis study tests whether adding a second immunotherapy drug (relatlimab) to the standard immunotherapy (nivolumab) can help keep nasopharyngeal cancer from growing or spreading for a longer time. About 156 people with recurrent or metastatic Epstein-Barr virus-associated nasophar…
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 10, 2026 13:29 UTC
-
Cholesterol drug boosts immunotherapy in head and neck cancer trial
Disease control Recruiting nowThis study tests whether adding lovastatin (a common cholesterol drug) to pembrolizumab (an immunotherapy) can shrink tumors in people with head and neck cancer that has returned or spread. About 28 adults whose cancer has a specific marker (PD-L1 CPS ≥ 1) will receive both drugs…
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 08, 2026 13:17 UTC
-
Remote hearing tests could save cancer Patients' hearing
Knowledge-focused Recruiting nowThis study looks at whether offering hearing tests near home or online can help more head and neck cancer patients get their hearing checked during treatment. Chemotherapy and radiation can cause hearing loss, but regular monitoring can catch it early. The study will enroll 118 a…
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Phase: NA • Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 12, 2026 12:05 UTC
-
Can a simple exercise prevent swallowing problems? study seeks answers.
Knowledge-focused Recruiting nowThis study looks at why some head and neck cancer patients stick with swallowing exercises after radiation, while others don't. Researchers will use blood tests and questionnaires to explore how immune proteins, emotions, and social support affect a patient's ability to follow th…
Matched conditions: STAGE IV NASOPHARYNGEAL CARCINOMA AJCC V8
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 10, 2026 13:27 UTC